Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Boehringer Ingelheim is acquiring T3 Pharmaceuticals, a Swiss developer of engineered bacteria-based cancer therapies, in a deal worth up to about…
Boehringer Ingelheim has agreed to buy Swiss biotech T3 Pharmaceuticals in a deal worth up to CHF 450 million (roughly $508 million), expanding the German…
First-in-human Phase 1/2 study of T3P-Y058-739, a genetically-modified, live attenuated strain of Yersinia enterocolitica, in patients with advanced solid…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Boehringer Ingelheim acquired Swiss biotech T3 Pharmaceuticals AG for up to CHF 450M (~$508M), gaining T3P-Y058-739, a Phase 1/2 engineered live-bacterial cancer therapy for advanced solid tumors. The asset is a genetically-modified, live attenuated strain of Yersinia enterocolitica that uses the bacterial type III secretion system to micro-inject immunomodulatory proteins (RIG-I CARD and cGAS, driving type I interferon production) directly into the tumor microenvironment while sparing healthy tissue. The buyout, which builds on a research collaboration running since 2018, deepens Boehringer's cancer-immunology portfolio with a non-checkpoint platform modality. Upfront undisclosed; milestone-based portion ~$268M. As of April 2026 the first-in-human study (NCT05120596) remained recruiting, evaluating intratumoral and intravenous monotherapy plus a pembrolizumab combination, with primary completion estimated for early 2027.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boehringer Ingelheim International GmbH / T3 Pharmaceuticals AG (this deal) | 2023 | $508M | — |
| Boehringer Ingelheim International GmbH / Sanofi SA (Merial Animal Health) | 2015 | $12.4B | 81 |
| Boehringer Ingelheim International GmbH / Abexxa Biologics Inc. | 2021 | — | — |
| Boehringer Ingelheim International GmbH / Cue Biopharma, Inc. | 2025 | $357M | — |
| Boehringer Ingelheim International GmbH / Synaffix B.V. | 2025 | $1.3B | — |
| Boehringer Ingelheim International GmbH / Immunitas Therapeutics, Inc. | 2026 | — | — |
| Boehringer Ingelheim International GmbH / Immunai Inc. | 2026 | $15M | — |
← Browse all deals · How we score deals
More: 2023 deals · Boehringer Ingelheim International GmbH deals · Oncology deals